ArticleTranslational andrology and urology2026
Real-world effectiveness of rezvilutamide plus androgen deprivation therapy in patients with high-volume metastatic hormone-sensitive prostate cancer: a retrospective multicenter cohort study.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rezvilutamide has demonstrated significant clinical benefits in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) in the phase III CHART study. However, patients enrolled in clinical trials may not fully represent those encountered in routine clinical practice, and real-world evidence in this population remains limited. This study aimed to evaluate the real-world effectiveness of rezvilutamide in combination with androgen deprivation therapy (ADT) in patients with high-volume mHSPC. Methods: This multicenter retrospective cohort study included patients with high-volume mHSPC who received rezvilutamide plus ADT between August 29, 2023, and April 1, 2026 across 21 offline centers and one online center in China. Outcomes included prostate-specific antigen (PSA) 50 (defined as a ≥50% decline from baseline), PSA90 (defined as a ≥90% decline from baseline), and undetectable PSA (PSA <0.2 ng/mL) rates at 3, 6, 9, and 12 months, as well as the 12-month PSA progression-free rate. Prespecified subgroup analyses were performed according to age, Eastern Cooperative Oncology Group performance status, and Gleason score. Results: A total of 1,888 patients were included, with a median age of 73 years [interquartile range (IQR), 68-79 years]. The median baseline PSA was 70.9 ng/mL (IQR, 5.9-146.0 ng/mL). At 3 months, the PSA50, PSA90, and undetectable PSA rates were 83.3% [1,572/1,888, 95% exact confidence interval (CI): 81.5-84.9%], 71.7% (1,353/1,888, 95% exact CI: 69.6-73.7%), and 44.8% (845/1,888, 95% exact CI: 42.5-47.1%), respectively. Overall, the PSA response rates showed a gradual increasing trend over time. By month 12, the PSA50, PSA90, and undetectable PSA rates had reached 86.0% (282/328, 95% exact CI: 81.7-89.6%), 78.7% (258/328, 95% exact CI: 73.8-83.0%), and 72.0% (236/328, 95% exact CI: 66.8-76.8%), respectively. The PSA progression-free rate at 12 months was 93.4%. Conclusions: These real-world findings support the clinical utility of rezvilutamide combined with ADT in achieving durable PSA suppression in patients with high-volume mHSPC. However, the absence of comprehensive safety data and the retrospective nature of the study warrant cautious interpretation, and further prospective validation is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.